Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Len Neckers

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2008
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneAkihiro Yano, Shinji Tsutsumi, Shiro Soga, et al.
Blood|April 9, 2004
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibCem Akin, Gerard Fumo, Akif S Yavuz, et al.
Cell Stress & Chaperones|June 14, 2015
Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome AtlasHarvey Schwartz, Brad Scroggins, Abbey Zuehlke, et al.
Plos One|November 22, 2011
ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancerFumitaka Koga, Soichiro Yoshida, Manabu Tatokoro, et al.
Journal of the National Cancer Institute|October 9, 2012
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavirJoong Sup Shim, Rajini Rao, Kristin Beebe, et al.
Cell Cycle (Georgetown, Tex.)|October 19, 2010
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinomaCarole Sourbier, Vladimir Valera-Romero, Alessio Giubellino, et al.
Cell Cycle (Georgetown, Tex.)|December 3, 2011
Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapySoichiro Yoshida, Fumitaka Koga, Manabu Tatokoro, et al.
Cancer Science|July 19, 2008
Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activationYukihiro Asami, Hideaki Kakeya, Yusuke Komi, et al.
Cell Stress & Chaperones|June 15, 2024
An update on the status of HSP90 inhibitors in cancer clinical trialsShraddha Rastogi, Abhinav Joshi, Nahoko Sato, et al.
Chembiochem : a European Journal of Chemical Biology|October 27, 2009
Inhibition of HSP90 with pochoximes: SAR and structure-based insightsSofia Barluenga, Jean-Gonzague Fontaine, Cuihua Wang, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2008
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneAkihiro Yano, Shinji Tsutsumi, Shiro Soga, et al.
Blood|April 9, 2004
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibCem Akin, Gerard Fumo, Akif S Yavuz, et al.
Cell Stress & Chaperones|June 14, 2015
Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome AtlasHarvey Schwartz, Brad Scroggins, Abbey Zuehlke, et al.
Plos One|November 22, 2011
ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancerFumitaka Koga, Soichiro Yoshida, Manabu Tatokoro, et al.
Journal of the National Cancer Institute|October 9, 2012
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavirJoong Sup Shim, Rajini Rao, Kristin Beebe, et al.
Cell Cycle (Georgetown, Tex.)|October 19, 2010
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinomaCarole Sourbier, Vladimir Valera-Romero, Alessio Giubellino, et al.
Cell Cycle (Georgetown, Tex.)|December 3, 2011
Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapySoichiro Yoshida, Fumitaka Koga, Manabu Tatokoro, et al.
Cancer Science|July 19, 2008
Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activationYukihiro Asami, Hideaki Kakeya, Yusuke Komi, et al.
Cell Stress & Chaperones|June 15, 2024
An update on the status of HSP90 inhibitors in cancer clinical trialsShraddha Rastogi, Abhinav Joshi, Nahoko Sato, et al.
Chembiochem : a European Journal of Chemical Biology|October 27, 2009
Inhibition of HSP90 with pochoximes: SAR and structure-based insightsSofia Barluenga, Jean-Gonzague Fontaine, Cuihua Wang, et al.
Pageof 17